Back to Search
Start Over
Angiographic variables predict increased riskfor adverse ischemic events after coronarystenting with glycoprotein IIb/IIIa inhibition
- Source :
- Journal of the American College of Cardiology. 42(6):981-988
- Publication Year :
- 2003
- Publisher :
- Elsevier BV, 2003.
-
Abstract
- OBJECTIVES We sought to assess whether pre-procedural angiographic characteristics are associated with adverse clinical outcomes after coronary stenting with glycoprotein IIb/IIIa inhibition. BACKGROUND Ischemic complications after balloon angioplasty are associated with pre- and post-procedural angiographic variables. However, in the current era of stenting with IIb/IIIa inhibition, it is unknown whether angiographic features assessed before intervention confer an increased risk of adverse procedural and subsequent clinical outcomes. METHODS In the Do Tirofiban and ReoPro Give Similar Efficacy Outcomes? Trial (TARGET), 4,809 patients undergoing planned stenting were randomized to tirofiban or abciximab. Baseline demographic, clinical, and angiographic variables were obtained. Clinical end points were recorded at 30 days and six months. The relationship between angiographic variables and adverse clinical outcomes was assessed. RESULTS Patients with the combination of thrombus, lesion eccentricity, and lesion length >20 mm had a 21.4% composite incidence of death, myocardial infarction, or urgent target vessel revascularization (TVR) at 30 days, compared with 4.2% in those patients without these high-risk features (hazard ratio [HR] 3.24, p 20 mm (HR 1.89, p 20 mm are at high risk for ischemic outcomes after coronary stenting, despite IIb/IIIa inhibition. Further research into novel anti-thrombotic therapies or procedural strategies is necessary for these patients.
- Subjects :
- medicine.medical_specialty
business.industry
medicine.medical_treatment
Stent
Tirofiban
medicine.disease
Surgery
law.invention
Clinical trial
Randomized controlled trial
law
Angioplasty
Internal medicine
Abciximab
Cardiology
Medicine
Myocardial infarction
Glycoprotein IIb/IIIa
business
Cardiology and Cardiovascular Medicine
medicine.drug
Subjects
Details
- ISSN :
- 07351097
- Volume :
- 42
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Journal of the American College of Cardiology
- Accession number :
- edsair.doi.dedup.....1ab0f24e680bab741bf332008eb0abf0
- Full Text :
- https://doi.org/10.1016/s0735-1097(03)00913-6